ARGX
ARGENX SE
$893.52
-0.60%
$55.5B
No data for this timeframe.
Vol
Market Cap$55.5B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders50 funds
Inst. Value$15.7B
Inst. Activity24 buys / 15 sells
SEC Reports5
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. P7·CIK 0001697862·Prev Close $898.94
Recent Activity
Jun 3, 2026
SEC
Argenx presented new long-term data for efgartigimod in myositis (ALKIVIA+ open-label extension) and Sjogren's disease (
6-K — Impact 5/10
May 6, 2026
SEC
argenx announced results of its Annual General Meeting and the appointment of Karen Massey as CEO, succeeding founder Ti
6-K — Impact 3/10
May 6, 2026
SEC
argenx announced leadership transition at its AGM: Karen Massey appointed CEO, Tim Van Hauwermeiren becomes Chair. Share
PRESS-RELEASE — Impact 2/10
Inst.
WELLINGTON MANAGEMENT GROUP LLP — ADD
1,021,457 shares ($745.9M)
Inst.
Invesco Ltd. — ADD
594,697 shares ($434.3M)
Jun 3, 2026
other
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
<p><b>June 3, 2026, 7:00 AM CEST</b></p>
May 8, 2026
Press
FDA approved label expansion for VYVGART and VYVGART Hytrulo to treat all serotypes of generalized myasthenia gravis (gM
Impact 7/10
Aug 8, 2024
Event
VYVGART
Supplemental Approval — Efficacy — EFGARTIGIMOD ALFA — INJECTABLE — INTRAVENOUS
Price Targets
$1,028.52
+15.1% upside
Buy
Current $893.52
Low $688.25
Median $1,017.68
High $1,285.92
22 analysts
$688.25
$1,285.92
Analyst Ratings
8Strong Buy
15Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 11, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| Jun 4, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| Jun 1, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| May 15, 2026 | Evercore ISI Group | MAINTAIN | Outperform → Outperform |
| May 8, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $5.22 ▲ +8.7% | $4.43 — $6.35 | 60% YoY | 14 |
| Next Q | $5.78 ▲ +3.3% | $4.21 — $7.02 | 30% YoY | 13 |
| Current FY | $22.04 ▲ +2.7% | $16.76 — $25.15 | 33% YoY | 17 |
| Next FY | $31.80 ▲ +12.2% | $22.65 — $70.48 | 44% YoY | 17 |
Latest Reports
BULLISH
6-K
5/10
Argenx presented new long-term data for efgartigimod in myositis (ALKIVIA+ open-label extension) and Sjogren's disease (
Jun 3, 2026
BULLISH
Press
7/10
FDA approved label expansion for VYVGART and VYVGART Hytrulo to treat all serotypes of generalized myasthenia gravis (gM
May 8, 2026
NEUTRAL
6-K
3/10
argenx announced results of its Annual General Meeting and the appointment of Karen Massey as CEO, succeeding founder Ti
May 6, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $3.6B | — |
| JANUS HENDERSON GROUP PLC | $1.8B | — |
| Capital World Investors | $1.6B | — |
| Artisan Partners Limited Partnership | $1.1B | — |
| WELLINGTON MANAGEMENT GROUP LLP | $745.9M | ADD |
50 institutional holders with $15.7B total value (21,483,223 shares) as of 2026-Q1. Top holders: FMR, JANUS, Capital. Net buying activity: 24 institutions added/increased vs 15 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 4,991,034 | $3.6B | 23.2% | — |
| 2 | JANUS HENDERSON GROUP PLC | 2,541,732 | $1.8B | 11.7% | — |
| 3 | Capital World Investors | 2,256,216 | $1.6B | 10.5% | — |
| 4 | Artisan Partners Limited Partnership | 1,467,982 | $1.1B | 6.8% | — |
| 5 | WELLINGTON MANAGEMENT GROUP LLP | 1,021,457 | $745.9M | 4.7% | ADD +50.4% |
| 6 | Avoro Capital Advisors LLC | 1,000,000 | $730.3M | 4.6% | — |
| 7 | BlackRock, Inc. | 808,337 | $590.3M | 3.8% | ADD +40.4% |
| 8 | RTW INVESTMENTS, LP | 709,446 | $518.1M | 3.3% | — |
| 9 | Invesco Ltd. | 594,697 | $434.3M | 2.8% | ADD +42.8% |
| 10 | MORGAN STANLEY | 560,711 | $409.5M | 2.6% | — |
| 11 | ALLIANCEBERNSTEIN L.P. | 422,304 | $355.1M | 2.3% | DOUBLED +388.7% |
| 12 | BANK OF AMERICA CORP /DE/ | 400,117 | $292.2M | 1.9% | — |
| 13 | SEI INVESTMENTS CO | 286,966 | $209.6M | 1.3% | — |
| 14 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 266,067 | $194.4M | 1.2% | NEW |
| 15 | JENNISON ASSOCIATES LLC | 237,468 | $173.4M | 1.1% | — |
| 16 | FRANKLIN RESOURCES INC | 233,493 | $170.5M | 1.1% | — |
| 17 | GOLDMAN SACHS GROUP INC | 231,985 | $169.4M | 1.1% | — |
| 18 | Clearbridge Investments, LLC | 231,356 | $168.9M | 1.1% | TRIM -55.0% |
| 19 | CITADEL ADVISORS LLC | 219,126 | $160.0M | 1.0% | — |
| 20 | AMERIPRISE FINANCIAL INC | 215,910 | $157.7M | 1.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | ADD | 679,236 | 1,021,457 | +50.4% | $745.9M | 2026-Q1 |
| Invesco Ltd. | ADD | 416,408 | 594,697 | +42.8% | $434.3M | 2026-Q1 |
| Clearbridge Investments, LLC | TRIM | 513,764 | 231,356 | -55.0% | $168.9M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | ADD | 53,902 | 107,195 | +98.9% | $78.3M | 2026-Q1 |
| PINEBRIDGE INVESTMENTS LLC | ADD | 72,040 | 103,812 | +44.1% | $75.8M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | NEW | — | 90,000 | — | $65.7M | 2026-Q1 |
| BANK OF MONTREAL /CAN/ | DOUBLED | 16,377 | 85,333 | +421.1% | $62.3M | 2026-Q1 |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | DOUBLED | 36,600 | 73,300 | +100.3% | $53.5M | 2026-Q1 |
| Amundi | ADD | 42,485 | 61,433 | +44.6% | $44.9M | 2026-Q1 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | ADD | 45,315 | 58,374 | +28.8% | $42.6M | 2026-Q1 |
| Hudson Bay Capital Management LP | ADD | 21,822 | 30,000 | +37.5% | $21.9M | 2026-Q1 |
| LMR Partners LLP | DOUBLED | 3,806 | 23,488 | +517.1% | $17.2M | 2026-Q1 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | ADD | 14,112 | 22,651 | +60.5% | $16.5M | 2026-Q1 |
| HSBC HOLDINGS PLC | NEW | — | 20,379 | — | $14.9M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | ADD | 11,552 | 21,023 | +82.0% | $14.8M | 2026-Q1 |
| Assenagon Asset Management S.A. | TRIM | 24,347 | 14,786 | -39.3% | $10.8M | 2026-Q1 |
| Allianz Asset Management GmbH | DOUBLED | 3,001 | 14,401 | +379.9% | $10.5M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 41,923 | 13,111 | -68.7% | $9.6M | 2026-Q1 |
| Trexquant Investment LP | DOUBLED | 1,109 | 7,009 | +532.0% | $5.1M | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | NEAR_EXIT | 169,098 | 5,545 | -96.7% | $4.0M | 2026-Q1 |
| M&T BANK CORP | NEAR_EXIT | 778,610 | 5,003 | -99.4% | $3.7M | 2026-Q1 |
| Varma Mutual Pension Insurance Co | ADD | 4,000 | 5,000 | +25.0% | $3.7M | 2026-Q1 |
| Jain Global LLC | NEAR_EXIT | 58,250 | 4,641 | -92.0% | $3.4M | 2026-Q1 |
| RHUMBLINE ADVISERS | DOUBLED | 1,829 | 3,752 | +105.1% | $2.7M | 2026-Q1 |
| Orion Porfolio Solutions, LLC | TRIM | 7,273 | 3,730 | -48.7% | $2.7M | 2026-Q1 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 5.2/10.
BULLISH
6-K
5/10
Argenx presented new long-term data for efgartigimod in myositis (ALKIVIA+ open-label extension) and
Jun 3, 2026
NEUTRAL
6-K
3/10
argenx announced results of its Annual General Meeting and the appointment of Karen Massey as CEO, s
May 6, 2026
NEUTRAL
PRESS-RELEASE
2/10
argenx announced leadership transition at its AGM: Karen Massey appointed CEO, Tim Van Hauwermeiren
May 6, 2026
BULLISH
PRESS-RELEASE
8/10
argenx reported Q4 2025 EPS of $8.02, a 91.2% beat vs the $4.19 consensus, with revenue of $1.12B in
Apr 30, 2026
BULLISH
6-K
8/10
argenx announced positive Phase 3 data from the ADAPT OCULUS and ADAPT SERON trials showing VYVGART'
Apr 20, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 25 analysts: 8 strong buy, 15 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$1,028.52 mean target
+15.1% upside
Buy (1.50)
$688.25 Low
$1,285.92 High
| Metric | Value |
|---|---|
| Current Price | $893.52 |
| Target Low | $688.25 |
| Target Mean | $1,028.52 |
| Target Median | $1,017.68 |
| Target High | $1,285.92 |
| # Analysts | 22 |
| Recommendation | Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$5.22 | $4.43 | $6.35 | 60.3% | +8.7% | 10↑ 2↓ | $1.2B | 46.3% | 14 |
| Next Q 2026-09-30 |
$5.78 | $4.21 | $7.02 | 30.1% | +3.3% | 7↑ 5↓ | $1.3B | 35.1% | 13 |
| Current FY 2026-12-31 |
$22.04 | $16.76 | $25.15 | 32.9% | +2.7% | 11↑ 4↓ | $5.1B | 41.9% | 17 |
| Next FY 2027-12-31 |
$31.80 | $22.65 | $70.48 | 44.3% | +12.2% | 9↑ 5↓ | $6.2B | 21.6% | 17 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $5.221 | |
| 7d ago | $5.205 | +0.016 |
| 30d ago | $4.804 | +0.417 |
| 60d ago | $4.865 | +0.356 |
| 90d ago | $4.993 | +0.228 |
11 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 11, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Jun 4, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Jun 1, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| May 15, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| May 8, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| May 8, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Apr 2, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Mar 9, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Feb 27, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 27, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 27, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Feb 27, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Feb 27, 2026 | Baird | MAINTAIN | Neutral | Neutral |
| Feb 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 20, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 14, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Jan 8, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Jan 8, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | Baird | DOWNGRADE | Outperform | Neutral |
| Dec 17, 2025 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Dec 16, 2025 | Wells Fargo | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 15 | 2 | 0 | 0 | 92% | |
| May 1, 2026 | 8 | 15 | 2 | 0 | 0 | 92% | |
| Apr 1, 2026 | 8 | 15 | 2 | 0 | 0 | 92% | |
| Mar 1, 2026 | 8 | 14 | 3 | 0 | 0 | 88% | |
| Feb 1, 2026 | 8 | 14 | 3 | 0 | 0 | 88% | |
| Jan 1, 2026 | 8 | 14 | 3 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
other
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
<p><b>June 3, 2026, 7:00 AM CEST</b></p>
Jun 3, 2026
Clinical Trial
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: Empasiprubart (Phase 3)
Trial: A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
Sponsor: argenx
Phase: Phase
May 31, 2026
Clinical Trial
A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
Phase Phase 3 — COMPLETED
May 31, 2026
clinical_trial_readout
Results Pending: efgartigimod (Phase 3) — Completed 81d ago
Trial: A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
Sponsor: arge
May 28, 2026
other
argenx to Host Myositis R&D Webinar on June 23, 2026
<p align="justify"><b>May 28, 2026</b><br><br><b>Amsterdam, the Netherlands</b> – argenx (Euronext & Nasdaq: ARGX), a global immunology company co
May 28, 2026
Clinical Trial
An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis
Phase Phase 3 — COMPLETED
May 27, 2026
other
argenx to Present at Upcoming Investor Conferences
<p align="justify"><b>May 27, 2026</b><br><br><b>Amsterdam, the Netherlands</b> – argenx (Euronext & Nasdaq: ARGX), a global immunology company co
May 11, 2026
Clinical Trial
A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase Phase 2 — ACTIVE_NOT_RECRUITING
May 11, 2026
clinical_trial_readout
T-90d Trial Readout: ARGX-119 (Phase 2)
Trial: A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
Sponsor: argenx
Phase: Phase 2 | Status: ACT
May 8, 2026
Clinical Trial
A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy
Phase Phase 2 — COMPLETED
May 8, 2026
fda
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
<p align="justify"><b>May 8, 2026, 5:20 PM CET</b></p>
May 6, 2026
other
argenx to Present at BofA Securities 2026 Health Care Conference
<p align="justify"><b>May 6, 2026</b><br><br><b>Amsterdam, the Netherlands</b> – argenx (Euronext & Nasdaq: ARGX), a global immunology company com
May 6, 2026
earnings
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
<p align="center"><i>Leadership transition marks next evolution of growth</i></p>
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: ARGX-119 (Phase 2)
Trial: A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
Sponsor: argenx
Phase: Phase 2 | Status: ACT
May 3, 2026
clinical_trial_readout
T-90d Trial Readout: ARGX-119 (Phase 2)
Trial: A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
Sponsor: argenx
Phase: Phase 2 | Status: ACT
May 1, 2026
clinical_trial_readout
Results Pending: efgartigimod (Phase 3) — Completed 51d ago
Trial: A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
Sponsor: arge
Apr 30, 2026
earnings
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
<p align="justify"><b>April 30, 2026</b><br><br><b>Amsterdam, the Netherlands</b> – argenx (Euronext & Nasdaq: ARGX), a global immunology company
Apr 20, 2026
short_interest
FTD: ARGX — 14,930 shares ($12.7M) failed to deliver
Settlement: 20260420, Price: $849.04, FTD Value: $12,676,167.2, ARGENX SE SPONSORED ADS (NLD)
Apr 18, 2026
other
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
<p><b>April 18, 2026, 7:00 AM CEST</b></p>
Aug 8, 2024
FDA
VYVGART
Supplemental Approval — Efficacy — EFGARTIGIMOD ALFA — INJECTABLE — INTRAVENOUS
Jun 21, 2024
FDA
VYVGART HYTRULO
Supplemental Approval — Efficacy — EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT) — INJECTABLE — SUBCUTANEOUS